Katelin A Mirkin1, Franklyn E Luke2, Alexandra Gangi3, Jose M Pimiento3, Daniel Jeong4, Christopher S Hollenbeak5, Joyce Wong1. 1. Department of Surgery, Division of General Surgery Specialties and Surgical Oncology, The Pennsylvania State University, College of Medicine, Hershey, PA, USA. 2. Department of Radiology, The Pennsylvania State University, College of Medicine, Hershey, PA, USA. 3. Department of Surgery, Moffitt Cancer Center, Tampa, FL, USA. 4. Department of Radiology, Moffitt Cancer Center, Tampa, FL, USA. 5. Department of Surgery and Public Health Sciences, The Pennsylvania State University, College of Medicine, Hershey, PA, USA.
Abstract
BACKGROUND: This study's objective was to evaluate the change in sarcopenia score following neoadjuvant chemotherapy (NAC) and to correlate both sarcopenia and change in score with perioperative outcomes in patients with advanced resected gastric cancer. METHODS: Multi-institutional analysis of patients with gastric cancer who underwent NAC and resection from 2000-2015 was performed. Demographic and perioperative data were included. Sarcopenia score was defined as CT measurement of total psoas muscle at L3, stratified by height (m). Sarcopenia was defined as a score <385 mm2/m2 in women and <545 mm2/m2 in men. RESULTS: Of 36 patients, 19% were sarcopenic prior to NAC. Following NAC, 31% were sarcopenic, with 14% developing sarcopenia during NAC. One patient (3%) became non-sarcopenic. There were no significant differences in patient, disease, or surgery characteristics between patients who were sarcopenic vs. not. Patients with sarcopenia were more likely to have post-operative complications (P=0.05). There was no significant difference in hospital stay (P=0.7402) or survival (P=0.2317). CONCLUSIONS: A significant number of patients with gastric cancer become sarcopenic during NAC. Although patients with sarcopenia were nearly twice as likely to develop post-operative complications, this did not appear to impact length of stay (LOS) or survival.
BACKGROUND: This study's objective was to evaluate the change in sarcopenia score following neoadjuvant chemotherapy (NAC) and to correlate both sarcopenia and change in score with perioperative outcomes in patients with advanced resected gastric cancer. METHODS: Multi-institutional analysis of patients with gastric cancer who underwent NAC and resection from 2000-2015 was performed. Demographic and perioperative data were included. Sarcopenia score was defined as CT measurement of total psoas muscle at L3, stratified by height (m). Sarcopenia was defined as a score <385 mm2/m2 in women and <545 mm2/m2 in men. RESULTS: Of 36 patients, 19% were sarcopenic prior to NAC. Following NAC, 31% were sarcopenic, with 14% developing sarcopenia during NAC. One patient (3%) became non-sarcopenic. There were no significant differences in patient, disease, or surgery characteristics between patients who were sarcopenic vs. not. Patients with sarcopenia were more likely to have post-operative complications (P=0.05). There was no significant difference in hospital stay (P=0.7402) or survival (P=0.2317). CONCLUSIONS: A significant number of patients with gastric cancer become sarcopenic during NAC. Although patients with sarcopenia were nearly twice as likely to develop post-operative complications, this did not appear to impact length of stay (LOS) or survival.
Authors: Peter D Peng; Mark G van Vledder; Susan Tsai; Mechteld C de Jong; Martin Makary; Julie Ng; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Michael A Choti; Ihab Kamel; Timothy M Pawlik Journal: HPB (Oxford) Date: 2011-03-29 Impact factor: 3.647
Authors: Kenneth Fearon; Florian Strasser; Stefan D Anker; Ingvar Bosaeus; Eduardo Bruera; Robin L Fainsinger; Aminah Jatoi; Charles Loprinzi; Neil MacDonald; Giovanni Mantovani; Mellar Davis; Maurizio Muscaritoli; Faith Ottery; Lukas Radbruch; Paula Ravasco; Declan Walsh; Andrew Wilcock; Stein Kaasa; Vickie E Baracos Journal: Lancet Oncol Date: 2011-02-04 Impact factor: 41.316
Authors: B H L Tan; K Brammer; N Randhawa; N T Welch; S L Parsons; E J James; J A Catton Journal: Eur J Surg Oncol Date: 2014-11-26 Impact factor: 4.424
Authors: Connie Yip; Vicky Goh; Andrew Davies; James Gossage; Rosalind Mitchell-Hay; Orla Hynes; Nick Maisey; Paul Ross; Andrew Gaya; David B Landau; Gary J Cook; Nyree Griffin; Robert Mason Journal: Eur Radiol Date: 2014-02-18 Impact factor: 5.315
Authors: Florian Huemer; Stefan Hecht; Bernhard Scharinger; Verena Schlintl; Gabriel Rinnerthaler; Konstantin Schlick; Ronald Heregger; Thomas Melchardt; Angela Wimmer; Iris Mühlbacher; Oliver Owen Koch; Daniel Neureiter; Eckhard Klieser; Sara Seyedinia; Mohsen Beheshti; Richard Greil; Lukas Weiss Journal: J Cancer Res Clin Oncol Date: 2022-07-21 Impact factor: 4.322
Authors: Christine Koch; Cornelius Reitz; Teresa Schreckenbach; Katrin Eichler; Natalie Filmann; Salah-Eddin Al-Batran; Thorsten Götze; Stefan Zeuzem; Wolf Otto Bechstein; Thomas Kraus; Jörg Bojunga; Markus Düx; Jörg Trojan; Irina Blumenstein Journal: PLoS One Date: 2019-10-22 Impact factor: 3.240
Authors: Alicia S Borggreve; Robin B den Boer; Gijs I van Boxel; Pim A de Jong; Wouter B Veldhuis; Elles Steenhagen; Richard van Hillegersberg; Jelle P Ruurda Journal: J Clin Med Date: 2020-01-11 Impact factor: 4.241